Adults 18 to 110, any sex, with Alzheimer Disease or Dementia. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in Caregiver MasteryPrimary· pre-randomization; 3 months post-randomization; and 6 months post-randomization (6 months post-randomization for Emory site only)
Caregiving competence scale, minimum and maximum values 4-16, higher scores mean greater mastery.
Scores at baseline
Group
Value
95% CI
Tele-Savvy Group
10.9
± 2.1
Attention Control Group
11.5
± 2.0
Scores at 3-month follow-up
Group
Value
95% CI
Tele-Savvy Group
12.4
± 2.0
Attention Control Group
12.0
± 2.0
Scores at 6-month follow-up
Group
Value
95% CI
Tele-Savvy Group
12.7
± 1.3
Attention Control Group
12.8
± 2.7
Change in Caregiver ReactionsSecondary· pre-randomization; 3 months post-randomization; and 6 months post-randomization (6 months post-randomization for Emory site only)
The reactions caregivers have to the behavioral and psychological symptoms expressed by persons living with dementia, were assessed using the Revised Memory and Behavior Problem Checklist (RMBPC). The RMBPC is a 24-item scale capturing caregiver reactions to 24 memory and behavior problems. Scores are computed based on the presence or absence of each problem first, and then for caregiver "reaction" or the extent to which caregivers were "bothered" or "upset" by each endorsed behavior. Reactions are assessed by asking how "upsetting" each behavior is to the caregiver on a Likert scale of 0 to 4
Scores at baseline
Group
Value
95% CI
Tele-Savvy Group
22.4
± 10.9
Attention Control Group
19.4
± 12.3
Scores at 3-month follow-up
Group
Value
95% CI
Tele-Savvy Group
17.6
± 12.2
Attention Control Group
9.4
± 13.0
Scores at 6-month follow-up
Group
Value
95% CI
Tele-Savvy Group
17.2
± 8.7
Attention Control Group
10.1
± 7.3
Change in Caregiver StressSecondary· pre-randomization; 3 months post-randomization; and 6 months post-randomization (6-month post randomization for Emory site only)
The Perceived Stress Scale (PSS) is a 14-item instrument designed to measure the degree to which situations in one's life are appraised as stressful. Higher score reflects higher perceived stress. PSS items were designed to tap the degree to which respondents found their lives unpredictable, uncontrollable, and overloading. The scale also includes a number of direct queries about current levels of experienced stress. Each item is scored from 0 (never) to 4 (very often), for a possible score range of 0-56, with higher scores meaning worse outcomes.
Scores at baseline
Group
Value
95% CI
Tele-Savvy Group
25.6
± 6.6
Attention Control Group
24.5
± 9.5
Scores at 3-month follow-up
Group
Value
95% CI
Tele-Savvy Group
21.1
± 5.5
Attention Control Group
15.2
± 7.3
Scores at 6-month follow-up
Group
Value
95% CI
Tele-Savvy Group
19.9
± 5.7
Attention Control Group
16.8
± 9.2
Sponsor's own description
This cluster randomized pragmatic clinical trial will test the effectiveness and feasibility of embedding the Tele-Savvy intervention, a psychoeducational program for family and other informal caregivers of older adults living in the community with Alzheimer's disease and related dementia (ADRD), in two health care systems/clinical sites: UConn Health in Farmington, Connecticut, and Emory Healthcare in Atlanta, Georgia.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT03033875 — Testing Tele-Savvy, an On-line Psychoeducation Program for Dementia Family Caregivers
· NA
· completed
Other recruiting trials for Alzheimer Disease
Currently open trials in the same condition.
NCT07290387 — Tele-Savvy for Latino Caregivers
· NA
· recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
· NA
· recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease
· NA
· recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
· Phase 3
· recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
· NA
· recruiting
Other UConn Health trials
Trials by the same sponsor.
NCT06115252 — Partnering to Enhance Emerging Adults' Response to Programs
· NA
· recruiting
NCT04598074 — Opioid Package Prototype (OPP)
· NA
· not yet recruiting
NCT06846853 — Gadopiclenol vs. Gadobutrol for Dynamic Contrast-Enhanced Pituitary MRI (Magnetic Resonance Imaging)
· Phase 4
· recruiting
NCT06731764 — Novel Approaches to the Treatment of Hypothyroidism
· Phase 2, PHASE3
· recruiting
NCT06668194 — Effect of Force Magnitude on Canine Retraction and Gingival Crevicular Fluid Proteome
· NA
· recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by UConn Health
Last refreshed: 14 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05080777.